Jeroen Bosch Ziekenhuis — Clinical Trial Site

114 Registered trials

54 Currently recruiting

Organisation

Jeroen Bosch Ziekenhuis

Location

's-Hertogenbosch, Netherlands

Identifier

ORG-100028922

Address

Henri Dunantstraat 1, 5223 GZ, Netherlands

Departments

#2922:Cardiology
3022: Neurology
Afdeling Longgeneeskunde
Cardiology
Chirurgie
Department of Medical Oncology
Department of Pulmonary Diseases
Department of Surgery
Gastroeneterology
gastroenterology
General Internal Medicine and Endocrinology
Gynaecology
Gynaecology oncology
Gynecology and obstetrics
Hematology
ICU
Infectious diseases
Intensive Care
Intern Oncology
Internal Medicine
Internal Medicine/ Oncology-Hematology
JBZ
Jeroen Bosch Ziekenhuis, dept. Internal medicine
Longgeneeskunde
Longoncologie
Medical oncology
Medische Oncologie
N/A
NA
Nephrology
Neurologie
Neurology
NLD002:Pulmonology
Obstetrics & Gynecology
Oncologie
Oncologie/hematologie
Oncology
polikliniek Cardiologie, route B.1.3, ruimtenummer B2.01.076
Polikliniek Longziekten, Gebouw C, etage 1
Pulmonary Medicine
Pulmonolgy
Pulmonology
Reproductive medicine and gynecology
Research Cardiology
Respiratory Diseases
Surgery
Trialbureau oncologie
Urology
Vascular Surgery

Clinical trials at this site (114)

Search interface

Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended

2023-507933-12-00 Advanced or Metastatic Non-small Cell Lung Cancer (NSCL 5 2022-08-18
SEQUEL-Breast: a phase 2 study on the combination of alpelisib and fulvestrant after progression on previous therapy with fulvestrant in pat… Ended

2024-514965-20-00 Breast cancer 4 2022-06-02
LEGACY Ended

2023-504360-42-00 Non-ST-segment elevation acute coronary syndrome 6 2022-05-13
Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended

2023-503517-30-00 Extensive-stage small-cell lung cancer 5 2022-04-01
Personalized dosing of ocrelizumab in MS Ended

2024-513193-22-00 Multiple Sclerosis 11 2022-03-16
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic… Ended

2023-506752-24-00 Locally recurrent inoperable or metastatic HR+/HER2- br 5 2021-08-05
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11
A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients … Ended

2023-506576-27-00 EGFR-mutated locally advanced or metastatic Non Small C 5 2020-09-30
A Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy with or without Pembrolizumab (LIBRETTO-431) Ended

2023-506783-14-00 Advanced or Metastatic RET Fusion-Positive Non-Small Ce 5 2020-02-24
HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended

2022-502478-18-00 Acute Myeloid Leukemia (AML) 4 2019-12-20
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in unfit… Ended

2023-503829-18-00 Acute myeloid leukemia 4 2019-12-05
Image‐guided de‐escalation of neoadjuvant chemotherapy in HER2‐positive breast cancer: the TRAIN‐3 study Ended

2024-516205-23-00 Breast cancer 4 2019-04-09
This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with alre… Ended

2023-509349-11-00 Previously untreated Chronic Lymphocytic Leukemia Witho 5 2019-03-22
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Acute myeloid leukemia 5 2019-03-01
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Foll… Ended

2023-509602-29-00 Patients with Limited Stage Small-Cell Lung Cancer (LS- 5 2019-02-11
Treatment with carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering Multi… Ended

2024-511334-12-00 Smoldering Multiple Myeloma 4 2018-11-19
HOVON 151 DLBCL: A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diff… Ended

2022-501076-26-00 high risk diffuse large B-cell lymphoma 4 2018-08-28
HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly d… Ended

2022-501038-48-00 Diffuse Large B-Cell Lymphoma 4 2018-07-26
Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended

2024-516204-42-00 Breast cancer 5 2017-11-21
CRITICS-II Ended

2023-503248-15-00 Patients with TNM 8th ed stage IB-IIC gastric adenocaci 4 2017-10-09
Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; P… Ended

2023-510159-53-01 peritoneal dissemination in stomach cancer patients 4 2017-09-28
Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospect… Ended

2023-510434-83-00 Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) 6 2016-10-17
Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended

2023-507889-89-00 Respiratory tract infection 5 2016-02-19
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lun… Ended

2023-505981-26-00 Non−Small Cell Lung Cancer 5 2015-11-20